Local Officials Join in Fight Against High Drug Prices
High drug costs in the US result from a number of factors and face criticism from many different parties. Recently, [...]
Kathy High Reflects on Career and Future of Gene Therapy
Kathy High recently joined AskBio (Asklepios BioPharmaceutical, Inc.) as president after a long and successful career in gene therapy research. [...]
Survey Results Will Be Announced in February
There’s not always a “right answer” to a problem. A survey explored how participants might respond to a marketing colleague [...]
Germany Announces RWE Data Collection for Novartis Zolgensma Gene Therapy
Germany’s Federal Joint Committee (GBA, Gemeinsamer Bundesausschuss) has announced a new registry study related to spinal muscular atrophy (SMA) drugs. [...]
Cytel’s Advanced Design Framework to Improve Clinical Trials
Cytel has released its Advanced Design Framework as a method to minimize failed clinical trials. Ideally, biostatisticians are involved in [...]
2021 Medication Access Report Details Obstacles
The newly released 2021 Medication Access Report is now available. It details the challenges that people might face in accessing [...]
Racial and Ethnic Disparities and Possible Solutions in Light of the COVID-19 Crisis
Many studies have been undertaken to better understand the effects of the COVID-19 pandemic. It has also been noted that [...]
A Conversation with Scientist.com Founder and CEO Kevin Lustig
The Biotech 2050 podcast had a candid conversation with Kevin Lustig, Founder and CEO of Scientist.com, which recently acquired HealthEconomics.Com. [...]
Changes in HealthCore Leadership
Mark Cziraky was vice president of scientific affairs, chief growth officer, and co-founder of HealthCore, Inc. He has transitioned to [...]
[Whitepaper] Caring for Polychronic Patients
Patients with more than a single chronic disease require a different type of care. Understanding the challenges of this patient [...]
[Whitepaper] Leadership Strategies for Crisis
A white paper from Optum provides strategies for organization leaders to make decisions in times of crisis. “This report focuses [...]
RWE Provides Architecture for Healthcare Decisions
The many types of data resulting from RWE (real world evidence) provide substantial information for healthcare institutions, regulators, and pharmaceutical companies, [...]
Using Artificial Intelligence to Inform COVID-19 Patient Care
COVID-19 has prompted the use of AI (Artificial Intelligence) in several facets of the pandemic—in addition to tracking cases, it [...]
2021 Drug Pricing Outlook to Prompt Pharma Action
2021 is expected to bring change to the drug pricing sphere—exactly when and how is still not entirely known. What [...]
COVID-19 Vaccines Bring Hope and Uncertainty
Although several vaccines for COVID-19 were rapidly created, tested, and received FDA emergency approval, vaccine hesitation remains a massive issue [...]
FDA’s CDER Releases 2021 Guidance Calendar
The FDA (Food and Drug Administration)’s CDER (Center for Drug Evaluation and Research has released its guidance calendar for 2021. [...]
Perspectives on Usable RWD in COVID-19 Era at Aetion Summit
The massive amount of RWD (real world data) has been a growing issue in the past several years. The COVID-19 [...]
RWD in a COVID-19 World
COVID-19 has been linked to the development of other, non-respiratory diseases including heart attacks. Understanding this correlation requires real world [...]
Can User Guide for Biden Inform Drug Cost Policy?
Drug costs will be a point of policy for Biden’s administration. Although there are many theories and proposed solutions, reducing [...]
Tracking Costs of Common Drugs in the US Market
In a recent article, the authors discuss drug-pricing trends in medications. They restricted their study to brand-name medications used to [...]
Registration is Open for Asembia’s Specialty Pharmacy Summit
Register today for Asembia’s Specialty Pharmacy Summit. Earlybird rates are available through April 16th, 2021 for both member pharmacies and [...]
Are Budget Caps a Solution to Skyrocketing Health Costs?
Healthcare costs and access to health services continue to be major points of discussion. One proposed solution is that of [...]
NICE rejects MS drug Zeposia Citing Cost Concerns
Bristol Myers Squibb developed Zeoposia (ozanimod) for use in multiple sclerosis patients. NICE (National Institute for Health and Care Excellence) [...]
Positive Consequence of Senate Pharma Pricing Bill?
The Senate Finance Committee’s bill on drug pricing was co-authored and introduced by Chuck Grassley and Ron Wyden. The authors [...]
Are Authorized Generics a Solution to High Drug Costs?
In response to concerns over drug prices, some pharmaceutical companies have released authorized generics as alternatives to brand-name products. These [...]